Altimmune (ALT) Shares Outstanding (2010 - 2026)

Altimmune (ALT) has reported Shares Outstanding (Entity) for 17 consecutive years, with $130.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 67.32% year-over-year to $130.2 million; the TTM figure through Mar 2026 stood at $130.2 million (up 67.32% YoY), while the FY2025 annual figure was $88.1 million, up 21.77% from the prior year.
• Shares Outstanding (Entity) improved to $130.2 million in Q1 2026 per ALT's latest filing, from $88.1 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $130.2 million in Q1 2026 and bottomed at $43.2 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $68.1 million across 5 years, with a median of $70.9 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) increased 7.52% — and 2026, when it jumped 67.32%.
• Altimmune's Shares Outstanding (Entity) stood at $49.2 million in 2022, then grew by 8.23% to $53.2 million in 2023, then jumped by 35.88% to $72.4 million in 2024, then increased by 21.77% to $88.1 million in 2025, then jumped by 47.8% to $130.2 million in 2026.
• Business Quant data shows ALT's Shares Outstanding (Entity) at $130.2 million in Q1 2026, $88.1 million in Q4 2025, and $95.6 million in Q3 2025.